Skip to content
ClinCalc Pro
Menu
Ornithine decarboxylase inhibitor (topical hirsutism)

Eflornithine

Brand names: Vaniqa

Eflornithine is a topical cream used to reduce unwanted facial hirsutism in women.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It irreversibly inhibits ornithine decarboxylase in the hair follicle, slowing the rate of hair growth rather than removing existing hair.

Prescribing in practice

  • It controls rather than cures hirsutism; growth returns towards baseline after stopping, and treatment should be discontinued if no improvement is seen after a reasonable trial.
  • It is for facial application only and existing hair-removal methods may need to be continued alongside it.
  • Transient stinging, burning or acne-like eruptions at the application site are common and usually mild.

Monitoring

No laboratory monitoring is needed; review for clinical benefit after several weeks and for tolerability of local effects.

Counselling the patient

  • Effect is gradual and may take several weeks to become apparent.
  • Continue your usual hair-removal routine as the cream slows but does not remove hair.
  • Avoid getting the cream in the eyes or on broken skin and wash hands after applying.

Evidence & guidelines

Topical eflornithine is an established adjunct for facial hirsutism, supported by randomised controlled trial data demonstrating reduced hair growth versus vehicle.

Reference: NICE TA61; BAD; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.